Cowen analyst Joseph Thome reiterated an Outperform rating and $125.00 price target on Axsome Therapeutics (NASDAQ: AXSM) after the FDA ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Axsome Therapeutics (AXSM) Offers Investors Hope - Mizuho Securities August 23, 2021 9:43 AM Pre-Open Stock Movers 08/23: (TRIL) (XERS) (AXSM) Higher; (LYFT) (UBER) (BGS) Lower (more...)August 23, 2021 9:28 AM Form 8-K Axsome Therapeutics, For: Aug 23August 23, 2021 7:01 AM Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive DisorderAugust 23, 2021 6:00 AM